The value of biomarkers has radically changed the traditional drug development pathway.
Are you ready for the new reality?
Precision Medicine Group is the first scientific services company designed specifically to enable biomarker-informed drug development.
Biotech innovators need more than benchtop acumen. They need an integrated model capable of harnessing clinical and biological data and analyzing this information to extract critical insights.
Precision Medicine Group is the only molecule-to-market scientific services company built to accelerate today’s development process.
A breakthrough isn’t defined by its approval; it’s defined by its ability to change behaviors and improve results. That can only happen when the value of this breakthrough is expressed in a way that resonates to all constituencies, from physician to patient to payer.
The expertise of Precision Medicine Group goes beyond drug development. Our commercialization capabilities are focused on ensuring that medical innovations are recognized, valued, and accessible to patients.
Ready to develop
So are we.
NEXT-GEN CLINICAL DEVELOPMENT
Our drug and diagnostic development organization, Precision for Medicine, is an industry leader in the design, development and execution of biomarker-driven clinical development programs. Our integration of technology-enabled clinical trials, biomarker laboratories and advanced data sciences ensure clients accelerate time to market while reducing costs and managing risk.
Our commercially focused business, known as Precision Value & Health, blends sophisticated data science with deep industry expertise and award-winning creative to communicate the clinical and economic value of client products to providers, payers, consumers, investors and the scientific community at large.
News & Updates
August 6, 2019
Precision for Medicine Receives CIR (French Research Tax Credit) Accreditation
August 1, 2019
Precision for Medicine launches biospecimen solutions offering with acquisition of ProMedDx and GLAS
July 16, 2019
QuartzBio™, part of Precision for Medicine, Expands Computational Biology and Launches Boston Office